Factor V Activity Significantly Increased in Severe COVID-19

Rates of DVT/PE significantly higher for patients with COVID-19 and elevated factor V activity

blood cells

TUESDAY, Sept. 15, 2020 (HealthDay News) -- Factor V activity is significantly increased in patients with severe COVID-19, according to a study published online Aug. 24 in the American Journal of Hematology.

Jonathan A. Stefely, M.D., Ph.D., from Massachusetts General Hospital in Boston, and colleagues measured factor V, VIII, and X activity in a cohort of 102 consecutive inpatients with COVID-19; the cohort represented severe COVID-19, with high rates of ventilator use, line clots, deep vein thrombosis or pulmonary embolism (DVT/PE), and mortality (92, 47, 23, and 22 percent, respectively). In addition, contemporaneous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-negative controls and historical prepandemic controls were analyzed.

The researchers found that compared with contemporaneous controls, in COVID-19, factor V activity was significantly elevated (median, 150 versus 105 IU/dL). Significantly higher rates of DVT/PE were seen for patients with COVID-19 and factor V activity >150 IU/dL compared with those with factor V activity ≤150 IU/dL (33 versus 13 percent). Factor V activity was associated with SARS-CoV-2 viral load in a sex-dependent manner within the cohort. Subsequent reductions in factor V were associated with progression to disseminated intravascular coagulation and mortality.

"Our study reveals factor V perturbations as a previously unrecognized feature of severe COVID-19, adds a mechanistic candidate to ongoing investigations of COVID-19 coagulopathy with potential links to SARS-CoV-2 disease biology, and provides a foundation for future studies of COVID-19 coagulopathy diagnosis and biomarkers for guiding anticoagulation therapy in severe COVID-19," the authors write.

Abstract/Full Text (subscription or payment may be required)

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on September 15, 2020

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ